Table 3 Summary of 3-month landmark analyses of selected clinical studies of first-line TKI therapy
From: Biomarkers for determining the prognosis in chronic myelogenous leukemia
TKI | Study | Parameter | BCR-ABL1% (IS) at 3Â months | P value | |
|---|---|---|---|---|---|
Imatinib | Hammersmith Hospital [51] |  | ≤9.84% (n = 211) | >9.84% (n = 68) |  |
8-year OS | 93.3% | 56.9% | <0.001 | ||
|  | ≤9.54% (n = 208) | >9.54% (n = 71) |  | ||
8-year PFS | 92.8% | 57.0% | <0.001 | ||
|  | ≤8.58% (n = 169) | >8.58% (n = 79) |  | ||
8-year CCyR | 99.4% | 21.7% | <0.001 | ||
|  | ≤2.81% (n = 141) | >2.81% (n = 137) |  | ||
8-year MMR | 82.5% | 21.1% | <0.001 | ||
German CML Study IV [50] |  | >1-10% (n = 281) | >10% (n = 189) |  | |
5-year OS | 92% | 87% | 0.037 | ||
|  | >1-10% (n = 283) | >10% (n = 191) |  | ||
5-year PFS | 94% | 87% | 0.012 | ||
ENESTnda[52] |  | ≤10% (n = 176) | >10% (n = 88) |  | |
MMR by 2Â years | 58% | 21% | NR | ||
PFS at 3Â years | 97.7% | 83.8% | |||
OS at 3Â years | 98.9% | 84.8% | |||
DASISIONa[9] |  | ≤10% (n = 154) | >10% (n = 85) |  | |
AP/BC by 3Â years | 2.6% | 12.9% | NR | ||
PFS at 3Â years | 95.9% | 75.3% | <0.0001 | ||
OS at 3Â years | 96.0% | 88.0% | 0.0036 | ||
BELAa[53] |  | ≤10% (n = 146) | >10% (n =77) |  | |
MMR by 24Â months | 69% | 17% | <0.001 | ||
CCyR by 12Â months | 95% | 65% | <0.001 | ||
OS at 24Â months | 99% | 95% | NS | ||
Nilotinib | ENESTnd [52] |  | ≤10% (n = 234) | >10% (n = 24) |  |
MMR by 2Â years | 80% | 29% | NR | ||
PFS at 3Â years | 95.9% | 82.9% | |||
OS at 3Â years | 97.6% | 86.7% | |||
Dasatinib | DASISION [9] |  | ≤10% (n = 198) | >10% (n = 37) |  |
AP/BC by 3Â years | 3.0% | 13.5% | NR | ||
PFS at 3Â years | 93.1% | 68.2% | 0.0003 | ||
OS at 3Â years | 95.9% | 85.9% | 0.0348 | ||
Bosutinib | BELA [53] |  | ≤10% (n = 179) | >10% (n =29) |  |
MMR by 24Â months | 74% | 21% | <0.001 | ||
CCyR by 12Â months | 96% | 48% | <0.001 | ||
OS at 24Â months | 99% | 88% | 0.004 | ||